Retatrutide introduced a new dysesthesia signal at ~21% at 12 mg and had the highest discontinuation rate (18.2%)

For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another

The most frequently studied doses are 1 mg, 4 mg, 8 mg, 12 mg, and 16 mg, all administered once a week
Schedule your medical weight loss consultation with Maribel Dixon, MSN, APRN FNP-C at South Beach Wellness Center
Gastrointestinal Complications: Although generally manageable, patients should be advised about common side effects like nausea and diarrhea